Novo obesity drug seen with 43 percent chance of approval
COPENHAGEN (Reuters) - Danish group Novo Nordisk's diabetes drug Victoza has a 43 percent chance of being approved as an obesity treatment in the United States, according to a Reuters poll which found Danish bank analysts had the highest expectations. (Source: Reuters: Health)
Novel epinephrine auto-injector (NEA): sharps injury prevention validation and comparable analysis with epipen and twinject.
Authors: Chipps BE
PMID: 21875554 [PubMed - in process] (Source: Annals of Allergy, Asthma and Immunology)
